文献速递心境障碍

全身麻醉与氯胺酮神经生理效应的分离成分

General Anesthesia and Discrete Components of Ketamine Neurophysiology.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

该队列研究基于3项前瞻性研究的数据,分析全身麻醉(GA)对氯胺酮脑电(EEG)特征的影响。主要分析纳入52名健康志愿者、择期手术患者及抑郁症患者,补充分析纳入27人。结果显示GA选择性保留氯胺酮的βγ功率调制,但消除其θ功率增强效应。

要点

  • GA下给予氯胺酮仍保留βγ功率调制,但缺乏特征性θ功率增强。
  • 该发现提示氯胺酮的θ与βγ神经生理成分可被麻醉分离。
  • 可能为开发更靶向的氯胺酮相关疗法提供探索方法。

核心结论

  • 氯胺酮与GA合用选择性调节θ而非βγ神经生理相关成分,提示可探索这些成分在行为效应中的作用。

研究设计与样本

  • 队列研究,对2017至2023年间3项前瞻性研究进行 participant-level 数据的二次分析。
  • 主要分析纳入2个队列(密歇根大学和斯坦福大学)共52名≥18岁健康志愿者、择期手术患者及抑郁症患者。
  • 补充分析纳入第3个队列(奥克兰大学)27名参与者。

主要发现

  • 主要分析52名参与者中,GA差异性改变了所有参与者(100%)常见的氯胺酮相关EEG特征。
  • 与清醒给药相比,GA下给药保留βγ功率调制:清醒时从6.3(11.3)增至11.6(2.2)dB,GA下从8.5(2.9)增至11.2(3.8)dB。
  • GA下给药缺乏特征性θ增强:清醒时从17.3(10.5)增至22.9(3.1)dB,GA下从29.0(3.0)非显著降至27.8(3.5)dB。

关键数值与推荐

  • 暴露为40分钟内亚麻醉剂量氯胺酮静脉输注(0.5 mg/kg体重)或安慰剂,伴或不伴GA。
  • 主要结局为药物输注期间EEG频带功率变化,采用Wilcoxon符号秩检验计算。

临床怎么用

  • 提示麻醉状态下氯胺酮的θ与βγ神经生理效应可分离,为研究其治疗机制提供方法学线索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ketamine has well-known dissociative, analgesic, and antidepressant properties, but it is unknown whether the neurophysiologic effects that are associated with these properties can be modulated separately from one another. Considering that specific cortical oscillations have been associated with specific therapeutic effects, modulating selective aspects of ketamine neurophysiology could inform efforts to develop more targeted therapies. OBJECTIVE: To determine whether the neurophysiologic signatures of ketamine are associated with removal of conscious awareness using general anesthesia (GA). DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a secondary analysis of participant-level data from 3 prospective studies conducted between 2017 and 2023. The primary analysis included data from 2 study cohorts (University of Michigan and Stanford University), and the supplementary analysis included data from a third cohort (University of Auckland). The study cohorts included healthy volunteers, patients undergoing elective surgery, and patients with a diagnosis of depression (all aged ≥18 years). EXPOSURE: Participants received a subanesthetic infusion of ketamine (0.5 mg/kg body weight) over 40 minutes or placebo with or without GA. MAIN OUTCOMES AND MEASURES: The primary outcome was change in electroencephalographic (EEG) band power during medication infusion. Changes were computed using nonparametric paired statistical text (Wilcoxon signed-rank test). RESULTS: This study included 52 participants in the primary analysis (mean [SD] age, 43.4 [18.3] years; 34 females [65.4%]) and 27 additional participants in the supplementary analysis (mean [SD] age, 30.2 [8.2] years; 15 females [55.6%]). GA differentially altered EEG features commonly associated with ketamine in all 52 participants (100%) in the primary analysis. Compared with awake administration, ketamine administered during GA preserved its βγ power modulation (mean [SEM] increase from 6.3 [11.3] to 11.6 [2.2] dB for awake administration; increase from 8.5 [2.9] to 11.2 [3.8] dB for administration during GA) but lacked its characteristic θ augmentation (increase from 17.3 [10.5] to 22.9 [3.1] dB during awake administration; nonsignificant decrease from 29.0 [3.0] to 27.8 [3.5] dB for administration during GA). CONCLUSIONS AND RELEVANCE: In this cohort study, coadministration of ketamine with GA selectively modulated the θ but not the βγ neurophysiologic correlates of ketamine. These findings suggest a potential method to explore the role of these components in the behavioral effects of ketamine.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Deverett B, Li D, Lii TR, et al. General Anesthesia and Discrete Components of Ketamine Neurophysiology. JAMA Psychiatry. 2026. PMID: 41949829. doi:10.1001/jamapsychiatry.2026.0190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。